<DOC>
	<DOCNO>NCT02724163</DOCNO>
	<brief_summary>The main purpose study : 1 . To establish number dos gemtuzumab ozogamicin ( maximum 3 dos ) tolerate safety deliver combination cytarabine plus mitoxantrone liposomal daunorubicin induction 2 . To compare mitoxantrone ( anthracenedione ) &amp; cytarabine liposomal daunorubicin ( anthracycline ) &amp; cytarabine induction therapy . 3 . To compare single dose gemtuzumab ozogamicin optimum tolerate number dos gemtuzumab ozogamicin ( identify dose-finding study ) combine induction chemotherapy . 4 . To compare two consolidation regimen : high dose cytarabine ( HD Ara-C ) fludarabine &amp; cytarabine ( FLA ) standard risk patient . 5 . To compare toxicity effectiveness two haemopoietic stem cell transplant ( HSCT ) condition regimens different intensity : conventional myeloablative conditioning ( MAC ) busulfan/cyclophosphamide reduce intensity conditioning ( RIC ) fludarabine/busulfan .</brief_summary>
	<brief_title>International Randomised Phase III Clinical Trial Children With Acute Myeloid Leukaemia</brief_title>
	<detailed_description>MyeChild 01 international phase III clinical trial child acute myeloid leukaemia ( AML ) ; disease significant mortality . It compare two induction chemotherapy regimen : mitoxantrone cytarabine ( current standard treatment ) liposomal daunorubicin cytarabine . This test liposomal daunorubicin , believe less cardiotoxic similar conventional drug , although unproven . Patients respond well induction chemotherapy eligible randomisation two consolidation regimen : high dose cytarabine ( current standard treatment ) fludarabine cytarabine ( FLA ) ; regimen commonly use patient relapsed disease , test whether FLA effective front line therapy standard consolidation treatment . Patients cytogenetic feature associate high risk relapse respond sub-optimally induction treatment candidate haemopoietic stem cell transplant ( HSCT ) eligible randomisation compare two HSCT condition regimen : myeloablative conditioning ( MAC ) ( current UNited Kingdom ( UK ) standard ) reduce intensity conditioning ( RIC ) . HSCT consistently show benefit high risk patient mortality associate procedure outweigh advantage reduction relapse risk . This test whether reduce intensity condition improves survival reduce transplant related death without increase relapse rate . The trial incorporate dose find study gemtuzumab ozogamicin . The aim identify optimum tolerated number dos gemtuzumab ozogamicin ( total 3 dos ) , safely combine either induction chemotherapy regimen compare number dose one dose gemtuzumab ozogamicin . The intensity treatment direct cytogenetics/molecular genetics response assess minimal residual disease ( MRD ) level measure flow cytometry molecular methodology .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Inclusion criterion trial entry R1 randomisation . Diagnosis acute myeloid leukaemia ( AML ) /high risk Myelodysplastic syndrome ( MDS ) ( &gt; 10 % blast bone marrow ) /isolated myeloid sarcoma ( MS ) ( either de novo secondary ) . Age &lt; 18 year . No prior chemotherapy biological therapy AML permit protocol . Normal cardiac function define fractional shortening ≥28 % ejection fraction ≥55 % . Fit protocol chemotherapy . Documented negative pregnancy test female patient childbearing potential . Patient agree use effective contraception ( patient child bear potential ) . Written informed consent patient and/or parent/legal guardian . Inclusion criterion participation gemtuzumab ozogamicin dose find study : Centres must formally activate order take part embed dose escalation study . Please contact trial office information . Patient meet inclusion criterion trial entry . Age : ≥12 month major dose find study ≥ 12 week &lt; 12 month minor dose find study Karnofsky Lansky performance score ≥50 . Normal renal function define calculated creatinine clearance ≥90ml/min/1.73m2 . Normal hepatic function define total bilirubin ≤2.5 upper limit normal ( ULN ) age unless cause leukaemic involvement Gilbert 's syndrome similar disorder . Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤10 x ULN age . Written informed consent patient and/or parent/legal guardian . Inclusion criterion participation R2 ( randomisation yet open ) . Patient meet inclusion criterion trial entry Age ≥12 week . Karnofsky Lansky performance score ≥50 . Normal renal function define calculated creatinine clearance ≥90ml/min/1.73m2 . Normal hepatic function define total bilirubin ≤2.5 ULN age due leukaemic involvement Gilbert 's syndrome similar disorder . ALT AST ≤10 x ULN age . Written informed consent patient and/or parent/legal guardian . Inclusion criterion participation R3 . Patient meet inclusion criterion trial entry Induction treatment per MyeChild 01 protocol treat 2 course mitoxantrone &amp; cytarabine trial . Minimal residual disease ( MRD ) response ( perform MyeChild 01 centralise laboratory , see national MyeChild 01 Laboratory Manual ) : Patients good risk cytogenetics/molecular genetics MRD level &lt; 0.1 % flow course 2 , decrease transcript level &gt; 3 log course 2 informative molecular marker , without informative marker sufficient sensitivity flow MRD monitoring Patients intermediate risk cytogenetics/molecular genetics MRD level &lt; 0.1 % flow course 1 course 2 , decrease transcript level &gt; 3 log course 1 course 2 informative molecular marker , without informative marker sufficient sensitivity flow MRD monitoring . Written informed consent patient and/or parent/legal guardian . Inclusion criterion participation R4 . Patient meet inclusion criterion trial entry Induction treatment per MyeChild 01 protocol treat 1 2 course mitoxantrone &amp; cytarabine ± treatment intensification fludarabine , cytarabine &amp; idarubicin ( FLAIda ) trial . Patient complete remission ( CR ) CR incomplete blood count recovery ( CRi ) define &lt; 5 % blast confirm flow cytometry/ molecular/FISH bone marrow aspirate take within 6 week prior randomisation R4 . Patient meet one follow criterion candidate HSCT per protocol : High risk course 1 ( patient poor risk cytogenetics patient intermediate risk cytogenetics fail achieve CR/CRi ) . Intermediate risk cytogenetics MRD &gt; 0.1 % course 1 2 measure flow . If flow MRD marker sufficient sensitivity identify , molecular MRD marker sensitivity &gt; 0.1 % may use . Good risk cytogenetics flow MRD &gt; 0.1 % confirmed decrease molecular MRD &lt; 3 log rise transcript level course 3 despite treatment intensification ( FLAIda ) discussion Clinical Coordinators . Availability 910/10 human leukocyte antigen ( HLA ) match family unrelated donor 58/8 match cord blood unit adequate cell dose define protocol section 17.1 . Written informed consent patient and/or parent/legal guardian . Exclusion criterion randomisation Acute Promyelocytic Leukaemia . Myeloid Leukaemia Down Syndrome . Blast crisis chronic myeloid leukaemia . Relapsed refractory AML . Bone marrow failure syndrome . Prior anthracycline exposure would inhibit delivery study anthracyclines . Concurrent treatment administration experimental drug biological therapy AML . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acute Myeloid Leukaemia</keyword>
	<keyword>Children</keyword>
	<keyword>Gemtuzumab ozogamicin</keyword>
	<keyword>Liposomal daunorubicin</keyword>
	<keyword>Mitoxantrone</keyword>
	<keyword>Randomised control trial</keyword>
	<keyword>Risk stratification</keyword>
	<keyword>Minimal residual disease</keyword>
	<keyword>Stem cell transplant</keyword>
</DOC>